Long-Term Safety and Effectiveness of Emicizumab in Hemophilia A Management

Abstract

Hemophilia A is an X-linked hereditary condition caused by a deficiency of clotting factor VIII, which precipitates spontaneous bleeding of joints and muscles that has an especially devastating effect on human health. Conventional prophylactic intervention entails repeated intravenous factor VIII injections typically three to four times weekly, which may become cumbersome and result in inhibitor development. An alternative is emicizumab. Humanized bispecific monoclonal antibody emicizumab plays an outstanding role as a key therapy. It acts like activated factor VIII by bridging factor IXa and factor X and helping in strengthening clotting without requiring factor VIII. During subcutaneous treatment, the half-life of emicizumab is long, and the dosing interval is longer than IV and compliance is better. It is recommended for use as a prophylactic strategy for hemophilia A in the United States of America and Japan. Clinical trials, such as the HAVEN studies, confirm that emicizumab reduces bleeding episodes with a promising safety profile. Injection site reactions, headache, and fever are typical side effects that are mild to moderate. Notably, severe thrombotic events have not been observed with emicizumab, whereas such events have been reported with some other treatments. Emicizumab also has strong bleeding control in both minor and major surgeries, providing a more flexible therapy option. As a safe, effective, and simple self-administered approach, it promotes patients’ quality of life and decreases health care costs remarkably. It is being investigated for clinical indications beyond the current indications and could be used in other patient populations and in combination with different treatments.